BioCardia, Inc. BCDA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
-176.15
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | -$8.2M | — | -$7.4M | $895,000 |
| 2024 | $58,000 | -$7.9M | — | -$7.9M | $837,000 |
| 2023 | $477,000 | -$11.6M | — | -$10.0M | -$1.6M |
| 2022 | $1.4M | -$11.9M | — | -$10.6M | $4.9M |
| 2021 | $1.0M | -$12.6M | — | -$10.5M | $10.4M |
| 2020 | $145,000 | -$15.0M | — | -$12.4M | $19.2M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -176.15 (distress)
- Working capital / assets 0.088
- Retained earnings / assets -49.326
- EBIT / assets -2.425
- Equity / liabilities 0.355
Source: SEC EDGAR filings · CIK 0000925741 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.